John Sharp, M.D. (he/him)

  • Assistant Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine

Biography

Dr. Sharp completed his medical school at the University of California, Davis School of Medicine in Sacramento, CA. This was followed by an Internal Medicine residency at the University of California, Los Angeles where he was selected to serve as chief resident at the West Los Angeles Veterans Affairs Medical Center. 

He subsequently completed his Hematology and Medical Oncology fellowship at The Ohio State University in Columbus, OH, where he was selected for the T32 postdoctoral fellowship in clinical research.

Dr. Sharp conducts research to understand and improve outcomes for patients with various types of lymphoma through real-world outcomes studies and prospective clinical trials.

Education and training

  • Degrees

    • M.D., 2018, University of California, Davis School of Medicine

  • Residency

    • Internal Medicine, University of California, Los Angeles

  • Fellowship

    • Hematology and Medical Oncology, The Ohio State University

Memberships and associations:

  • American Board of Internal Medicine
  • American Society of Clinical Oncology
  • American Society of Hematology

Publications

Selected publications

  • Cliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, et al. Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma. Clin Cancer Res. 2026 Jan 6;32(1):159-168. doi: 10.1158/1078-0432.CCR-25-2392. PMID: 41143601; PMCID: PMC12624761.
  • Arnold ZJ, Lundberg J, Wiczer T, Handley D, Bond D, Sawalha Y, Sigmund A, Reneau J, Hanel W, Sharp J, Youssef Y, Alinari L, Brammer J, Christian B, Baiocchi R, Maddocks K, Epperla N, Voorhees TJ. Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate. J Oncol Pharm Pract. 2026 Feb 4:10781552261417588. doi: 10.1177/10781552261417588. Epub ahead of print. PMID: 41637279.
  • Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N. Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. Blood Adv. 2026 Jun 9;10(11):3757-3768. doi: 10.1182/bloodadvances.2025019115.
  • Umyarova E, Sharp J, Pei C, Pellegrino W, Zhao Q, Denlinger N, Voorhees T, De Lima M, Epperla N. Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies. Blood Cancer J. 2026 Mar 12;16(1):29. doi: 10.1038/s41408-026-01471-5. PMID: 41820357; PMCID: PMC12982786.
  • Hamby M, Egleston BL, Frosch ZAK, Steiner RE, Noy A, Carvajal V, Chong ER, Tolu SS, Jean-Louis G, Amengual JE, Patel R, Ahmed S, Sharp J, Voorhees T, et al. Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study. Blood Cancer J. 2026 Mar 23;16(1):43. doi: 10.1038/s41408-026-01457-3. PMID: 41872135; PMCID: PMC13031790.
  • Bock AM, Hao P, Xu Y, Luttwak E, Thiruvengadam SK, Sekaran K, Sano D, Vaughn J, Sharp J, Major A, Patel V, Smilnak G, et al. Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers. Hemasphere. 2026 Mar 31;10(4):e70346. doi: 10.1002/hem3.70346. PMID: 42038745; PMCID: PMC13103724.
  • Sharp J, Olszewski AJ, Epperla N. Identifying high-risk patients with MALT lymphoma undergoing first-line therapy for disease progression. Expert Review of Hematology. 2025 Aug 12; doi:10.1080/17474086.2025.2547834. PMID: 40793830.
  • Sharp J, Zhao Q, Voorhees TJ, Bond DA, Sawalha Y, Reneau J, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Brammer JE, Maddocks K, Christian B, Bezerra E, Denlinger N, Vasu S, De Lima M, Prosek J, Epperla N. Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma. Br J Haematol. 2025 Jun 30;. doi: 10.1111/bjh.20240. PMID: 40589093.
  • Sharp J, Shana'ah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla N. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. J Natl Compr Canc Netw. 2025 Jun 23;23(7). doi: 10.6004/jnccn.2025.7045. PMID: 40550489.
  • Tabbara N*, Sharp J*, Gaut D, Pham TTD, Tang K, Oliai C, Sim MS, Schiller G, Young P, Sasine JP. Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias. Am J Hematol. 2022 Jul;97(7):E249-E255. PMID: 35358346. (*co-first author)

Publications